• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    West Introduces Daikyo PLASCAP® RUV Closures in New Nested Format at Pharmapack

    1/22/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care
    Get the next $WST alert in real time by email

    EXTON, Pa., Jan. 22, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the introduction of Daikyo PLASCAP® Ready-to-Use Validated (RUV) closures in a new nested format available in multiple configurations at this year's Pharmapack event in Paris, France.  This marks West's latest product offering supporting the needs of advanced therapies, one of the fastest growing areas, driven by continued innovation in cell and gene therapy treatments.

    Daikyo PLASCAP RUV Closures (13mm & 20mm)

    The PLASCAP® closure is a metal-free polypropylene cap with an integrated stopper. This one-step press-fit solution for vial closure is offered in ready-to-use, validated formats compatible with vials with 13mm and 20 mm crowns. The new 6x8 nested tub configuration supports the West 10ml nested CZ vials as well as selected nested vials with a 20mm crown.

    "West has been a leader in pharmaceutical packaging for over 100 years, and our containment solutions are used for the majority of gene and viral therapies in the market," said Stacey Vaughan, Vice President of Strategic Portfolio Management. "The introduction of this new nested format for our PLASCAP closures addresses the complex challenges of containment for advanced therapy molecules while meeting increasing regulatory requirements of the market."  

    For more information about PLASCAP® click here.

    To learn more about West, please visit our website: www.westpharma.com.

    Forward-Looking Statements

    Certain forward-looking statements are included in this press release. They use words such as "supporting," "addresses," "meeting," and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations.  Specifically, there is no certainty that West's introduction of the PLASCAP® RUV closures in a new nested format will achieve any particular result.  These forward-looking statements involve a number of risks and uncertainties. Various factors could cause the actual results to differ materially from those expressed in, or underlying, these forward-looking statements, such as customer decisions to move forward with new products and product categories; average profitability, or mix, of the products offered for sale; dependence on third party suppliers and partners; interruptions or weaknesses in the supply chain; fluctuations in currency exchange; and the ability to meet development milestones with key customers. These important factors are not all inclusive. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2023. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

    About West  

    West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 43 billion components and devices each year.    

    Headquartered in Exton, Pennsylvania, West in its fiscal year 2023 generated $2.95 billion in net sales. West is traded on the New York Stock Exchange (NYSE:WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.   

    Crystal Zenith and PLASCAP are registered trademarks of Daikyo Seiko, Ltd. and are used under license.

    (PRNewsfoto/West Pharmaceutical Services, I)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/west-introduces-daikyo-plascap-ruv-closures-in-new-nested-format-at-pharmapack-302356582.html

    SOURCE West Pharmaceutical Services, Inc.

    Get the next $WST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WST

    DatePrice TargetRatingAnalyst
    12/2/2025$285.00Equal-Weight
    Morgan Stanley
    9/15/2025$311.00Buy
    Rothschild & Co Redburn
    6/24/2025$245.00Equal Weight
    Barclays
    3/18/2025$275.00Outperform
    Evercore ISI
    2/14/2025$250.00Hold → Buy
    Deutsche Bank
    1/8/2025$400.00Buy
    Citigroup
    12/13/2024Peer Perform
    Wolfe Research
    12/12/2024$350.00 → $390.00Neutral → Buy
    UBS
    More analyst ratings

    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on West Pharm with a new price target

    Morgan Stanley initiated coverage of West Pharm with a rating of Equal-Weight and set a new price target of $285.00

    12/2/25 8:36:52 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Rothschild & Co Redburn initiated coverage on West Pharm with a new price target

    Rothschild & Co Redburn initiated coverage of West Pharm with a rating of Buy and set a new price target of $311.00

    9/15/25 8:12:22 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on West Pharm with a new price target

    Barclays initiated coverage of West Pharm with a rating of Equal Weight and set a new price target of $245.00

    6/24/25 8:11:45 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    West Reports Fourth-Quarter and Full-Year 2025 Results

    – Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025. Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period) Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.Fourth-quarter diluted earnings per sha

    2/12/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West to Host Fourth-Quarter and Full-Year 2025 Conference Call

    EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registe

    1/29/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack

    Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products EXTON, Pa., Jan. 20, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced participation at Pharmapack 2026 in Paris, France to showcase its leadership and expertise on industry challenges and trends in packaging and containment. This event marks the global commercial availability of West Synchrony™ S1 prefillable syringe (PFS) system. West Synchrony S1 PFS system provides a broad product po

    1/20/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.

    SCHEDULE 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    10/31/25 11:41:37 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by West Pharmaceutical Services Inc.

    10-Q - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    10/23/25 4:14:52 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    10/23/25 7:15:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Haugen Janet Brutschea

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    1/5/26 12:37:29 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by SVP, GC & Corporate Secretary Finch Norman D. Jr.

    4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    12/10/25 10:33:41 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Finch Norman D. Jr.

    3 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)

    12/10/25 10:32:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Leadership Updates

    Live Leadership Updates

    View All

    West Welcomes Robert McMahon as Incoming Chief Financial Officer

    EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless transition.   "Bob is an accomplished CFO and business executive within the

    7/21/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Sotera Health Appoints Karen Flynn to Board of Directors

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    West Announces Executive Leadership Appointments

    EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

    5/12/22 4:30:00 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Financials

    Live finance-specific insights

    View All

    West Reports Fourth-Quarter and Full-Year 2025 Results

    – Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025. Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period) Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.Fourth-quarter diluted earnings per sha

    2/12/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West to Host Fourth-Quarter and Full-Year 2025 Conference Call

    EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registe

    1/29/26 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    West Declares Quarterly Dividend

    EXTON, Pa., Dec. 10, 2025 /PRNewswire/ -- On December 9, 2025, the board of directors of West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on February 4, 2026, to shareholders of record on January 28, 2026. About WestWest Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug devel

    12/10/25 6:00:00 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/13/24 5:17:38 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/14/23 12:37:59 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by West Pharmaceutical Services Inc. (Amendment)

    SC 13G/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Subject)

    2/10/22 8:47:14 AM ET
    $WST
    Medical/Dental Instruments
    Health Care